HiFiBiO Therapeutics

Proud to have our CEO Liang Schweizer selected as a winner in the Entrepreneur Of The Year® New England program! She joins an esteemed multi-industry community of other entrepreneurs who have driven their companies’ success, transformed their industries, and made a positive impact on their employees and communities! https://lnkd.in/eJ3BhqJS #EOYUS #EOYNE

June is #NationalCancerSurvivorMonth. Join HiFiBiO Therapeutics in honoring the over 18 million individuals in the U.S. living with a history of cancer and the unique challenges they continue to face (AACR https://lnkd.in/g-p7KKU). Thanks to remarkable advances in cancer research, there have been significant improvements in cancer diagnostics and treatment, particularly in the field of cancer immunotherapies. However, substantial gaps remain. Many patients harbor cancers that either do not respond to current standard immunotherapies or experience relapse, limiting the potential benefits (https://lnkd.in/ezt2uiyf). HiFiBiO Therapeutics is utilizing its DIS® translational platform to develop a pipeline of novel immune modulatory therapeutics aimed at overcoming these gaps. The company has advanced three cancer immunotherapies into Phase I trials, showing promising developments: the first-in-class anti-TNFR2 antibody HFB200301 (clinical trial NCT05238883), the next-generation OX40 agonist antibody HFB301001 (clinical trial NCT05229601), and the best-in-class BTLA antagonist antibody HFB200603 (clinical trial NCT05789069).    #hifibioway #cancer #cancerawareness #cancertreatment #cancersurvivor #innovation #immunotherapy 

Congratulations to our partner FibroGen, Inc. for receiving FDA clearance for FG-3165, a Gal-9 antagonist derived from HiFiBiO's HFB200902!   HiFiBiO Therapeutics embraces an open innovation model where our team works collaboratively with our partners globally to accelerate advances in immunotherapies. We are attending BIO if you are interested in exploring partnership opportunities! #openinnovation #immunotherapies #partnership

There was amazing buzz around our two posters at #ASCO2024! Our team enjoyed the exciting discussions around the results of our two Ph1 clinical trials for HFB200301, a best-in-class TNFR2 agonist and HFB301001, a next-generation OX40 agonist.    The e-posters are now up on our website for viewing.   HFB200301: https://lnkd.in/dPQmsECv   HFB301001: https://lnkd.in/deGb_wpH

Meet HiFiBiO's Timothy Miller at the upcoming #BIO2024 International Convention on June 3rd to 6th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!

Attending #ASCO2024? Don't forget to stop by our two posters as we present Phase 1 dose escalation data for our first-in-class TNFR2 agonist, HFB200301 and next-generation OX40 agonist HFB301001! Link to press release for details: https://lnkd.in/emRqZBs3

Reminder to stop by our two posters at #ASCO2024! HiFiBiO Therapeutics will present Phase 1 dose escalation data for two novel immuno-oncology agonists: a first-in-class TNFR2 agonist HFB200301 and a next-generation OX40 agonist HFB301001.    Link to press release and abstract: https://lnkd.in/emRqZBs3   #cancer #immunotherapy #innovation 

May is #AAPIHeritageMonth! Join HiFiBiO to celebrate all the Asian Americans, Native Hawaiians, and Pacific Islanders that have contributed greatly to our shared history.

Meet HiFiBiO's Timothy Miller at this year’s Pharma Partnering Summit on May 14th – 15th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!  #PharmaPartneringSummit #partnership #innovation 

Meet us at The Citizens JMP Life Sciences Conference on Monday, May 13th at 1:30pm ET! Robert Andtbacka, MD, CM, FACS, FRCSC will host a company presentation, and the leadership team will host 1x1 meetings with investors.